Navigation Links
Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid

BRIDGEWATER, N.J., May 03, 2007 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global specialty pharmaceutical company through its Pharmaceuticals Division, this week presented positive results of a pharmacokinetic study of its investigational abuse-deterrent, extended-release opioid at the 26th annual scientific meeting of the American Pain Society in Washington, D.C. The data demonstrated the release characteristics of this extended-release morphine sulfate plus sequestered naltrexone product were similar to that found in previous studies of Alpharma's currently marketed KADIAN(R) (morphine sulfate extended-release) Capsules.

"There is a clear need for new medications that provide pain relief while deterring abuse and we believe our technology may offer a significant abuse- deterrent option for physicians treating patients suffering from moderate-to- severe chronic pain," says Joseph Stauffer, DO, Chief Medical Officer Clinical Research & Medical Affairs and Senior Vice President, Alpharma Pharmaceuticals LLC. "We are committed to offering physicians the tools needed to treat patients with moderate-to-severe chronic pain."

Alpharma's proprietary technology combines an extended-release opioid with a sequestered core of the antagonist, naltrexone. If the product is taken as directed, it is intended that the naltrexone will remain sequestered and the patient will achieve pain relief similar to KADIAN(R) (morphine sulfate extended-release) Capsules. If the capsule is tampered with by crushing, chewing or dissolving, it is designed so that the naltrexone will be released and euphoria will be abated.

Study Design and Results

In the single-dose, open-label, two-period crossover study (fasted and fed) in eight healthy subjects, 21 to 45 years of age, after an overnight fast, subjects either received the study drug (containing 60 mg morphine sulfate) or consumed a standard high-cal orie, high-fat breakfast and took the study drug 30 minutes later. Blood samples for morphine pharmacokinetic analysis were drawn prior to dosing and at intervals from 0.5 to 168.0 hours post-dose.

The results of the pharmacokinetic analysis demonstrated, for both the fasted and fed states that the release characteristics of morphine were consistent with a sustained-release formulation and were similar to previous study results for KADIAN(R) (morphine sulfate extended-release) Capsules. Most naltrexone levels were below the assay measurement limits. Adverse events, reported in five subjects, were mild to moderate in intensity and resolved without treatment.

This study was conducted as part of Alpharma's medical development program for its abuse-deterrent morphine product, and its results were consistent with data generated in the Phase II clinical program for this product.. The company is targeting an NDA filing for its abuse-deterrent product in the first half of 2008.

Other Data Presented on KADIAN(R) Capsules

Also presented at the annual meeting were data that showed the extended- release properties of KADIAN(R) were maintained even in the presence of a significant quantity of alcohol. These results indicate that the concomitant use of tested levels of alcohol with KADIAN(R) has no significant impact on mean morphine blood levels or the timing of morphine release. Recently, the U.S. Food and Drug Administration completed a review of this data and concluded that the KADIAN(R) black box warning did not need to include any precautionary language related to alcohol.

About KADIAN(R) Capsules

KADIAN(R) capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate-to-severe pain, when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. The capsules can be taken once-daily (q24h) or twice-daily (q12h), as prescribed, to provide up to 24 hours o f pain relief. KADIAN(R) capsules are not for use as a prn analgesic.

KADIAN(R) capsules are available in eight strengths: 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, 100 mg and 200 mg. The 100 mg and 200 mg capsules are for use in opioid-tolerant patients only. KADIAN(R) offers flexible dosing and administration options that allow physicians to fine-tune titration schedules and tailor treatment for individual patient needs.

KADIAN(R) capsules may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression because respiratory depression, hypotension and profound sedation or coma may result.

KADIAN(R) side effects are generally consistent with those found with other opioids. The most common include drowsiness, constipation, nausea, dizziness and anxiety. Serious adverse reactions that may be associated with KADIAN(R) include respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, low blood pressure and/or shock.

KADIAN(R) capsules contain an opioid agonist which is a Schedule II controlled substance. KADIAN(R) has an abuse liability similar to other opioids. This should be considered when prescribing or dispensing KADIAN(R).

For complete prescribing information, visit www.KADIAN.com.

About Alpharma

Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded pharmaceutical franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world's leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.

  
  KADIAN(R) is a registered trademark.

    KADIAN is a trademark owned by Alpharma Pharmaceuticals LLC.



    Media inquiries:

    Shannon Coughlin

    HealthSTAR Public Relations

    646-722-8839

    


    Contact:

    Kathleen Makrakis - VP, Investor Relations

    

    908.566.3916

SCoughlin@healthstarpr.com kathleen.makrakis@alpharma.com

CONTACT: Media inquiries - Shannon Coughlin, HealthSTAR Public Relations,+1-646-722-8839, ; Kathleen Makrakis - VP,Investor Relations, +1-908-566-3916, SCoughlin@healthstarpr.com kathleen.makrakis@alpharma.com

Web site: http://www.KADIAN.com/http://www.alpharma.com/

Ticker Symbol: (NYSE:ALO)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):